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ABSTRACT
Background: The p16 tumor suppressor gene is an important negative regulator of the 
cell cycle. Inactivation of p16, especially via promoter hypermethylation, has been 
found in numerous human cancers such as breast, lung, colorectal, and liver.
Objectives: To determine the role of epigenetic methylation in p16 regulation in Ira-
nian patients with hepatocellular carcinoma (HCC).
Patients and Methods: The methylation pattern in the p16 gene promoter was analyzed 
by bisulfite direct sequencing in 43 paraffin-embedded formalin-fixed tissues from pa-
tients with HCC. In addition, normal specimens from liver graft donors were used as 
the control group.
Results: The bisulfite direct sequencing showed heterozygous hypermethylation in 
13.9% of individuals with HCC. Homozygous methylation within the GC-box IV was de-
tected in another 58.1% of the patients.
Conclusions: It is proposed that methylation, but not necessarily hypermethylation, 
may play a role in the down-regulation of the p16 gene promoter at least in some Ira-
nian patients with HCC.
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  Implication for health policy/practice/research/medical education:
Hypermethylation in the p16 promoter region has been reported to occur frequently in several human cancers such as HCC. We 
highly recommend  biologists and Gastroenterologists to study this article.
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(HBV) and/or the hepatitis C virus (HCV), excessive alco-
hol consumption, aflatoxin, and certain metabolic dis-
eases (2-5). Inactivation of tumor suppressor genes and 
activation of oncogenes initiated by genetic and epige-
netic differences may play an important role in carcino-
genesis. The p16ink4a gene is a tumor suppressor that 
acts as a negative regulator of the cell cycle by binding 
to and inhibiting cyclin-dependent kinase 4 (CDK4) (6). 
Reduced  expression  of  the  p16  gene  results  in  uncon-
trolled division of cells. Several mechanisms that lead 
to p16 inactivation have been described, including point 
mutations, homozygous deletions, and promoter hyper-
methylation (7-9), and hypermethylation of the p16 gene 
1. Background
Hepatocellular carcinoma (HCC), one of the most fatal 
human malignancies, is characterized by late presenta-
tion, fast progression, and limited response to therapy 
(1). HCC is commonly associated with the chronic liver 
diseases caused by infection with the hepatitis B virus Hepat Mon. 2011;11(9):719-723
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promoter has been shown to occur more frequently in 
HCC patients (10-12). The p16 gene promoter contains 5 
GC boxes, which are termed GCI to GCV. The boxes cover 
a region located upstream of the translational start site 
from nucleotide -474 to -1 (Figure 1) (13).
The first round of amplification was performed with 100 
ng of bisulfite-treated DNA. The primers for the first PCR 
were 5'-TTTTTAGAGGATTTGAGGGATAGG-3' (forward) and 
5'-CTACCTAATTCCAATTCCCCTACAAACTTC-3'  (reverse). 
The initial PCR conditions were as follows: 94°C for 1 min; 
5 cycles at 94°C for 45 s, 65°C for 45 s, and 72°C for 30 s; 5 
cycles at 94°C for 45 s, 64°C for 45 s, and 72°C for 30 s; and 
then 25 cycles at 94°C for 45 s, 63°C for 45 s, and 72°C for 30 
s, with final extension step at 72°C for 5 min. An aliquot of 
the PCR product was used as the template for the second 
(nested) PCR. The nested PCR was performed using 5'-
AGAAAGAGGAGGGGTTGGTTGG-3' as the forward primer 
and 5'-ACRCCCRCACCTCCTCTACC-3' as the reverse primer. 
Nested PCR was performed with an initial denaturing 
step at 94°C for 1 min, followed by 35 cycles at 94°C for 
45 s, 61°C for 45 s, and 72°C for 30 s. The subsequent cycle 
sequencing reaction was performed using an automatic 
sequencer (ABI Company).
3.4. Statistical Analysis
The  correlation  between  the  clinicopathological  pa 
rameters and p16 methylation was analyzed using the 
Chi-square test and Student’s t-test. A P < 0.05 was con-
sidered statistically significant.
4. Results
A total of 43 HCC patients were analyzed according to 
age, sex, cirrhosis, and hepatitis and tumor pathological 
grade. (Table 1) Among the affected individuals, the sex 
ratio was 28 males to 15 females, with an average age of 
48 years. Other HCC-related risk factors were as follows: 
cirrhosis (34.8%), hepatitis B infection (9.3%), and hepati-
tis C infection (2.3%). The samples were examined patho-
logically and classified as well differentiated HCC (n = 
24), moderately differentiated HCC (n = 14), and poorly 
differentiated HCC (n = 5).
A 191-bp region of the p16 gene promoter in archival PEFF 
samples from 43 HCC cases and an additional 20 control 
samples prepared from normal liver tissue was subject-
ed to bisulfite direct sequencing. We found heterozygous 
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Figure 1. An 800-bp Portion of the Human p16 Gene Promoter Located Up-
stream of the Initiation Codon. The Promoter Region Contains 5 Consensus 
GC Boxes, Which are Often the Targets for Methylation-Mediated Inactivation 
in Diverse Human Cancers, Including HCC.
2. Objectives
In the present study, we used direct bisulfite sequenc-
ing in order to detect the methylation patterns of GC box 
IV, GC box V, and a portion of exon 1 in the p16 gene pro-
moter in Iranian patients with HCC.
3. Patients and Methods
3.1. DNA Extraction
Paraffin-embedded  formalin-fixed  (PEFF)  tissues  from 
43 patients with HCC were collected from Namazi hos-
pital (Shiraz, Iran) between September 2005 and Decem-
ber 2009. For the controls, 20 normal liver tissue samples 
were obtained from volunteer liver graft donors. The do-
nors were brain dead, and their families allowed their 
organs to be donated. Sections (10 μm) were cut from the 
PEFF tissue blocks and were deparaffinized with xylene. 
Genomic DNA was extracted using a DNeasy Blood and 
Tissue Kit according to the manufacturer’s instructions 
(Qiagen, Valencia, CA, USA).
3.2. Bisulfite Modification
Bisulfite  modification  was  performed  based  on  the 
principle that bisulfite converts unmethylated cytosine 
residues to uracil, whereas methylated cytosine residues 
remain unaffected. Therefore, after bisulfite conversion, 
methylated  and  unmethylated  cytosines  were  deter-
mined by direct sequencing. Bisulfite treatment of DNA 
was performed according to the instructions in the Epi-
Tect Bisulfite Kit (Qiagen).
3.3. Bisulfite Direct Sequencing
In  the  bisulfite  direct  sequencing  method,  primers 
should be designed to amplify both methylated and un-
methylated sequences. In addition, they should not con-
tain CpG- cytosines, because they are not complemen-
tary to methylated cytosines, which are not affected by 
sodium bisulfite. Finally, after direct sequencing, all sites 
with unmethylated cytosines are displayed as thymines 
in the amplified sense strand and as adenines in the am-
plified antisense strand. A 191-basepair fragment in the 
p16 gene promoter, including 19 CpG dinucleotides, was 
amplified  by  nested  polymerase  chain  reaction  (PCR). 
HCC a Patients Normal Controls
Number of cases 43 20
Gender
Males
Females
28
15
14
6
Average age, y 48 45
Cirrhosis 15
Hepatitis B 4
Hepatitis C 1
Grade
Wd a 24
Md a 14
Pd a 5
Table 1. Characteristics of HCC Patients and the Control Group
a Abbreviations: HCC, hepatocellular carcinoma; Md, moderately differen-
tiated; Pd, poorly differentiated HCC; Wd, well differentiatedHepat Mon. 2011;11(9):719-723
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hypermethylation in 13.9% (n = 6) of the HCC samples, 
and homozygous methylation in GC-box IV was found in 
58.1% (n = 25) of the HCC samples. In contrast, we did not 
observe any modification in the normal samples (Figure 
2).
The clinical characteristics of patients who were posi-
tive  for  hypermethylation  and  GC-box  IV  methylation 
are listed in Table 2. No significant correlation was found 
between abnormal methylation in HCC and age, gender, 
or tumor grade.
5. Discussion
DNA methylation is a type of chemical DNA modifica-
tion in which a methyl group is added to carbon 5 of the 
cytosine ring. This reaction is carried out by a group of 
enzymes  called  DNA  methyltransferases,  which  regu-
late gene transcription through DNA methylation (14). 
Interest in the field of DNA methylation has increased 
significantly  in  recent  years  because  of  its  major  role 
in the cancer process (15, 16). Aberrant methylation pat-
terns  in  tumors  include  global  hypomethylation  and 
localized  hypermethylation  at  CpG  islands;  however, 
these 2 types of epigenetic abnormalities usually seem 
to affect different DNA sequences. In most cancer types, 
genomic hypomethylation usually appears in repeated 
DNA sequences, while hypermethylation is most often 
observed within the CpG islands in the promoter regions 
of genes, frequently tumor suppressor genes (17). In this 
context, p16 acts as a negative regulator of the cell cycle, 
and hypermethylation in the p16 promoter region has 
been reported to occur frequently in several human can-
cers such as HCC (18-20). In contrast, other studies have 
shown a low frequency of hypermethylation within the 
p16 gene in individuals with HCC (21).
No.
(n=43)
p16 Methylation/ 
hypermethylation (+)
p16 Methylation/ 
hypermethylation (-)
Chi-Square P value
Gender
Male
Female
28
15
20
11
8
4
0.02 0.05
Age, y
6–80 43 49.89 ± 5.22 a 45.67 ± 15.23 a 0.46 b ≥ 0.05
Cirrhosis
Affected
Not affected
15
28
8
19
7
9
0.99 > 0.05
Hepatitis B
Affected
Not affected
4
39
1
30
3
9
0c 0c
Hepatitis C
Affected
Not affected
1
42
0
31
1
11
0c 0c
Grade
Wd d
Md d
Pd d
24
14
5
16
11
4
8
3
2
0.84 >0.05
Table 2. Characteristics of Patients and Methylation and Hypermethylation of the p16 Gene Promoter of HCC Patients and the Control Group
a Mean ± SD 
b Student’s t-test
c Because of the low number of samples, it was not possible to calculate a P value.
d Abbreviations: Md, moderately differentiated; Pd, poorly differentiated HCC; Wd, well differentiated
Figure 2. (A) A Portion of the p16 Gene Promoter that was Heterozygously 
Methylated in the HCC Samples; (B) the Same Region of the Promoter in Nor-
mal Tissues was Unmethylated. (C) A Portion of the p16 Promoter that was 
Methylated within GC-Box IV. Asterisks Indicate Methylated Nucleotides.
(A)
(B)
(C)Hepat Mon. 2011;11(9):719-723
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In the current study, the methylation state of the p16 
gene promoter was analyzed by bisulfite direct sequenc-
ing  in  Iranian  patients  with  HCC.  In  13.9%  (n  =  6)  of 
samples, heterozygous hypermethylation was detected 
within the p16 gene promoter. Furthermore, DNA methy-
lation was observed within GC-box IV in 58.1% (n = 25) of 
tumor tissue samples. All normal samples were negative 
for every type of methylation tested. Therefore, we rea-
son that methylation in GC-box IV may sufficiently de-
crease the transcriptional activity of the p16 gene. Several 
reports have suggested that methylation of at least 1 cy-
tosine would significantly down-regulate p16 promoter 
activity (22). In general, RNA helicase A interacts with the 
regulatory region of genes and facilitates transcription 
activity, such that methylation would significantly alter 
the interaction between the enzyme and the substrate 
(23). On the basis of the abovementioned negative results 
in the normal specimens, we propose that methylation, 
but not necessarily hypermethylation, plays a role in the 
down-regulation of the p16 gene promoter at least in Ira-
nian individuals with HCC.
The methylation results have been compared to the clini-
copathological  features.  It  appears  that  cirrhosis  is  the 
most common risk factor for the development of HCC in 
our patients. Cirrhosis is a progressive disease that often 
leads to cancer (24). The frequency of hepatitis B (1.7–5%) 
and hepatitis C (0.5–1%) infection and aflatoxin contami-
nation could also explain the relatively high frequency of 
this disease in Iran (25). Among our patients, 6 were under 
the age of 18 years; 2 of them were affected with tyrosine-
mia type 1, and 1 of them had Fanconi anemia. All of the 
abovementioned factors and diseases have a negative in-
fluence on liver function and thus increase the probability 
of HCC. For the other 3 young patients, there is a possibil-
ity that they inherited an affected gene, in particular a tu-
mor suppressor gene. According to the 2 hit hypotheses, 
when an affected allele is inherited, the probability of sec-
ond allele inactivation via deletion (LOH), mutation, and/
or promoter hypermethylation increases (26). Statistical 
analysis also revealed no significant correlation between 
the presence of abnormal methylation in the affected tis-
sues and gender, age, and cirrhosis. Comparing p16 meth-
ylation and hypermethylation in the HCC tissues accord-
ing  to  tumor  grade,  methylation  or  hypermethylation 
was detected in 16 of 24 (61%) well differentiated HCCs, 11 of 
14 (78%) moderately differentiated HCCs, and 4 of 5 (80%) 
poorly differentiated HCCs. Therefore, there was no asso-
ciation between methylation or hypermethylation and tu-
mor grade. This indicates that methylation has a negative 
effect on gene expression, both in the primary stages of tu-
mor formation and during tumor progression. Finally, we 
assume that other mechanisms, such as LOH and/or point 
mutations, might be factors responsible for tumor sup-
pressor gene loss of function. However, additional evalu-
ation is needed to understand the role of the epigenetic 
factors that influence p16, in particular, and the onset of 
HCC in Iranian individuals in general.
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